Anidulafungin in the treatment of invasive fungal infections

References

• AlexanderBDSchellWAMillerJLCandida glabrata fungemia in transplant patients receiving voriconazole after fluconazoleTransplantation2005808687116210978
   PubMed Web of Science ®Google Scholar
• AndesDMarchilloKLowtherJIn vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis modelAntimicrob Agents Chemother20034711879212654645
   PubMed Web of Science ®Google Scholar
• ArathoonEGGotuzzoENoriegaLMRandomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasesAntimicrob Agents Chemother200246451711796357
   PubMed Web of Science ®Google Scholar
• BuellDKovandaLDrakeTAlternative day dosing of micafungin in the treatment of esophageal candidiasis200545th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstract M-719
   Google Scholar
• ClancyCJBarchiesiFFalconi DiFrancescoLClinical manifestations and molecular epidemiology of late recurrent candidemia, and implications for managementEur J Clin Microbiol Infect Dis2000195859211014620
   PubMed Web of Science ®Google Scholar
• de WetNLlanos-CuentasASuleimanJA randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patientsClin Infect Dis200439842915472817
   PubMed Web of Science ®Google Scholar
• DowellJStogniewMKrauseDAnidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment200313th European Congress of Clinical Microbiology and Infectious Diseases
   Google Scholar
• DowellJAKnebelWLuddenTPopulation pharmacokinetic analysis of anidulafungin, an echinocandin antifungalJ Clin Pharmacol200444590815145966
   PubMed Web of Science ®Google Scholar
• DowellJASchranzJBaruchASafety and pharmacokinetics of coadministered voriconazole and anidulafunginJ Clin Pharmacol20054513738216291712
   PubMed Web of Science ®Google Scholar
• DowellJAStogniewMKrauseDAnidulafungin (ANID) pharmacokinetic (PK)/Pharmacodynamic (PD) correlation: Treatment of esophageal candidiasis200343rd Interscience Conference of Antimicrobial Agents and Chemotherapy Abstract A-1578
   Google Scholar
• Espinel-IngroffAComparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeastsJ Clin Microbiol199836295069738049
   PubMed Web of Science ®Google Scholar
• Espinel-IngroffAIn vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literatureRev Iberoam Micol2003201213615456349
   PubMedGoogle Scholar
• GrollAHMickieneDPetraitieneRPharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma samplingAntimicrob Agents Chemother20014528455511557479
   PubMed Web of Science ®Google Scholar
• GumboTIkedaFLouieANightingaleCHMurakawaTAmbrosePGDrusanoGLGlucan synthase inhibitorsAntimicrobial Pharmacodynamics in Theory and Clinical Practice2007a2New YorkInforma Healthcare35577
   Google Scholar
• GumboTChemalyRFIsadaCMLate complications of Candida (Torulopsis) glabrata fungemia: description of a phenomenonScand J Infect Dis200234817812578150
   PubMed Web of Science ®Google Scholar
• GumboTDrusanoGLLiuWAnidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasisAntimicrob Agents Chemother200650369570016954319
   PubMed Web of Science ®Google Scholar
• GumboTIsadaCMHallGCandida glabrata Fungemia. Clinical features of 139 patientsMedicine (Baltimore)199978220710424204
   PubMed Web of Science ®Google Scholar
• GumboTDrusanoGLLiuWOnce-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropeniaAntimicrob Agents Chemother2007b519687417194830
   PubMed Web of Science ®Google Scholar
• KrauseDSReinhardtJVazquezJAPhase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemiaAntimicrob Agents Chemother2004a482021415155194
   PubMed Web of Science ®Google Scholar
• KrauseDSSimjeeAEvan RensburgCA randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasisClin Infect Dis2004b397707515472806
   PubMed Web of Science ®Google Scholar
• KurtzMBAbruzzoGFlatteryACharacterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studiesInfect Immun1996643244518757860
   PubMed Web of Science ®Google Scholar
• KuseERChetchotisakdPda CunhaCAMicafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trialLancet200736915192717482982
   PubMed Web of Science ®Google Scholar
• LouieADezielMLiuWPharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activityAntimicrob Agents Chemother20054950586816304173
   PubMed Web of Science ®Google Scholar
• Mora-DuarteJBettsRRotsteinCComparison of caspofungin and amphotericin B for invasive candidiasisN Engl J Med20023472020912490683
   PubMed Web of Science ®Google Scholar
• NasserRMMelgarGRLongworthDLIncidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemiaAm J Med199710325329236482
   PubMed Web of Science ®Google Scholar
• NguyenMHPeacockJEJrMorrisAJThe changing face of candidemia: emergence of non-Candida albicans species and antifungal resistanceAm J Med1996100617238678081
   PubMed Web of Science ®Google Scholar
• OakleyKLMooreCBDenningDWIn vitro activity of the echinocandin antifungal agent LY303, 366 in Comparison with itraconazole and amphotericin B against Aspergillus sppAntimicrob Agents Chemother1998422726309756785
   PubMed Web of Science ®Google Scholar
• PappasPGRotsteinCMBettsRFMicafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasisClin Infect Dis2007458839317806055
   PubMed Web of Science ®Google Scholar
• Pfizer IncFinal package insert for ERAXIS (anidulafungin) for injection2006New York
   Google Scholar
• PhillipsPShafranSGarberGMulticenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study GroupEur J Clin Microbiol Infect Dis199716337459228472
   PubMed Web of Science ®Google Scholar
• ReboliACRotsteinCPappasPGAnidulafungin versus fluconazole for invasive candidiasisN Engl J Med200735624728217568028
   PubMed Web of Science ®Google Scholar
• RexJHBennettJESugarAMA randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National InstituteN Engl J Med19943311325307935701
   PubMed Web of Science ®Google Scholar
• RexJHPappasPGKarchmerAWA randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjectsClin Infect Dis2003361221812746765
   PubMed Web of Science ®Google Scholar
• SerranoMCValverde-CondeAChavezMMIn vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus sppDiagn Microbiol Infect Dis200345131512614985
   PubMed Web of Science ®Google Scholar
• SobelJDBradshawSKLipkaCJCaspofungin in the treatment of symptomatic candiduriaClin Infect Dis200744e46e4917278048
   PubMed Web of Science ®Google Scholar
• SobelJDRevankarSGEchinocandins – first-choice or first-line therapy for invasive candidiasis?N Engl J Med20073562525617568034
   PubMed Web of Science ®Google Scholar
• TrisselLAOgundeleABCompatibility of anidulafungin with other drugs during simulated Y-site administrationAm J Health Syst Pharm200562834715821277
   PubMed Web of Science ®Google Scholar
• WiederholdNPKontoyiannisDPChiJPharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activityJ Infect Dis200419014647115378439
   PubMed Web of Science ®Google Scholar